PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Captopril - Hypertension
PAD Profile : Captopril - Hypertension Important
Important Information :
Not 1st line
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Aliskiren
- Bendroflumethiazide
- Candesartan cilexetil
- Eprosartan
- Indapamide
- Irbesartan
- Losartan potassium
- Olmesartan medoxomil
- Valsartan
- Ramipril
- Amlodipine
- Lisinopril
- Bisoprolol fumarate
- Doxazosin mesilate
- Diltiazem hydrochloride
- Nifedipine
- Perindopril erbumine
- Telmisartan
- Moxonidine
- Co-tenidone (Atenolol/chlortalidone)
- Enalapril maleate
- Quinapril hydrochloride
- Nebivolol
- Perindopril arginine
- Metolazone
- Azilsartan medoxomil
- Lercanidipine hydrochloride
- Nicardipine hydrochloride
- Chlortalidone
- Spironolactone
- Atenolol
- Carvedilol
- Celiprolol hydrochloride
- Metoprolol tartrate
- Propranolol hydrochloride
- Prazosin hydrochloride
- Clonidine hydrochloride
- Hydralazine hydrochloride
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
Associated BNF Codes
02. Cardiovascular System
02.05.05. Renin-angiotensin system drugs